Phase 2 trial, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, and efficacy of infigratinib, a fibroblast growth factor receptor (FGFR) 1-3-selective tyrosine kinase inhibitor

This study aims to investigate the degree and extent of spinal stenosis, chronic pain, sleep apnoea, impaired hearing, cardiovascular risk factors, and body composition in Norwegian adults with achondroplasia.

A Multi-center, Longitudinal, Observational Study of Children With Achondroplasia   Update - 21th Oct 2019 This is a long-term, multi-center, longitudinal, observational study in children with achondroplasia (ACH). The aim is to study height velocity and comorbidities in children with ACH. This is a natural history study and no study medication will be administered. All content in ClinicalTrials.gov identifier (NCT number): NCT03875534   […]

Prospective Clinical Assessment Study in Children With Achondroplasia - The PROPEL trial Update - 21st Oct 2019 This is a long-term, multi-center, observational study in children 2.5 to 10 years with achondroplasia (ACH). The objective is to evaluate growth, ACH-related medical complications, and treatments of study participants. No study medication will be administered. All content in ClinicalTrials.gov identifier (NCT number): NCT04035811   S […]

This is a study with the main purpose of creating an electronic registry for all types of bone conditions, starting with achondroplasia. This registry will include data on the natural history and treatment outcomes of these diseases.